Only three cycles of nivolumab showed remarkable durable response and reversible myeloradiculoneuropathy in a patient with metastatic papillary renal cell carcinoma type 2

INTRODUCTION: The efficacy of nivolumab for non‐clear cell renal cell carcinoma is still unclear. We present a rare case of metastatic papillary renal cell carcinoma remarkably responded to nivolumab but developed myeloradiculoneuropathy as immune‐related adverse event. CASE PRESENTATION: The patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Iwasaki, Kazunori, Shin, Toshitaka, Inoue, Toru, Shibuya, Tadamasa, Hirai, Kenichi, Ando, Tadasuke, Mimata, Hiromitsu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8088879/
https://www.ncbi.nlm.nih.gov/pubmed/33977240
http://dx.doi.org/10.1002/iju5.12262

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8088879/
https://www.ncbi.nlm.nih.gov/pubmed/33977240
http://dx.doi.org/10.1002/iju5.12262

Ejemplares similares